Further support for the statins as antiinflammatory and immunomodulatory agents: comment on the review by Abeles and Pillinger and the editorial by Arnaud and Mach.
Schikler
Kenneth N
KN
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007072:Immunoglobulin D / Q000235:genetics / Q000378:metabolism; D007155:Immunologic Factors / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000378:metabolism; D012216:Rheumatic Diseases / Q000188:drug therapy*; D019821:Simvastatin / Q000627:therapeutic use; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007072:Immunoglobulin D; D007155:Immunologic Factors; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D019821:Simvastatin; D017853:Phosphotransferases (Alcohol Group Acceptor); C021796:mevalonate kinase